‹ Screener

IceCure Medical Ltd.

ICCM · Surgical & Medical Instruments & Apparatus · EDGAR filings ↗

Grade

D44

Going-concern cryoablation device maker with deeply negative margins and roughly two quarters of cash.

Strengths

Risks

Notable findings

Key metrics

Gross margin
36.3%
Operating margin
-446.7%
Net margin
-445.6%
Return on equity
-166.4%
Return on assets
-108.4%
ROIC
-131.6%
Revenue growth (QoQ)
2.7%
Debt / equity
0.0×
Current ratio
2.6×
Free cash flow
-$15M
Tangible book value
$9M
Cash & investments
$9M
Cash runway
2q
Stock comp / revenue
40.6%

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT02399124 ↗Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma
Renal Cell Carcinoma
NAActive Not Recruiting2026-02-01
NCT07629206 ↗Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
Low-Risk, Early Stage Breast Cancer
NANot Yet Recruiting2034-07-01
NCT02200705 ↗Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Breast Cancer
NACompleted2024-03-17
NCT01735812 ↗Laparoscopic Cryoablation of Uterine Fibroids
Symptomatic Uterine Fibroids
NAWithdrawn2015-12-01
NCT01671943 ↗Cryotherapy for Breast Cancer Trial
Breast Carcinoma
NACompleted2014-07-01
NCT00910312 ↗ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial
Fibroadenoma
NACompleted2013-01-01

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Recent filings

FormFiledPeriodAccession
20-F2026-03-172025-12-310001213900-26-028684 ↗
20-F2025-03-272024-12-310001013762-25-003012 ↗
20-F2025-03-272024-12-310001013762-25-003010 ↗
20-F2024-04-032023-12-310001213900-24-029586 ↗
20-F2023-03-292022-12-310001213900-23-023867 ↗
20-F2022-04-012021-12-310001213900-22-017147 ↗